{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T08:15:30Z","timestamp":1772784930637,"version":"3.50.1"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T00:00:00Z","timestamp":1606089600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007475","name":"Canadian Dermatology Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007475","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008363","name":"Kr\u00e6ftens Bek\u00e6mpelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Mycosis fungoides (MF) is the most common cutaneous T-cell lymphoma, for which there is no cure. Immune checkpoint inhibitors have been tried in MF but the results have been inconsistent. To gain insight into the immunogenicity of MF we characterized the neoantigen landscape of this lymphoma, focusing on the known predictors of responses to immunotherapy: the quantity, HLA-binding strength and subclonality of neoantigens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Whole exome and whole transcriptome sequences were obtained from 24 MF samples (16 plaques, 8 tumors) from 13 patients. Bioinformatic pipelines (Mutect2, OptiType, MuPeXi) were used for mutation calling, HLA typing, and neoantigen prediction. PhyloWGS was used to subdivide malignant cells into stem and clades, to which neoantigens were matched to determine their clonality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>MF has a high mutational load (median 3,217 non synonymous mutations), resulting in a significant number of total neoantigens (median 1,309 per sample) and high-affinity neoantigens (median 328). In stage I disease most neoantigens were clonal but with stage progression, 75% of lesions had &amp;gt;50% subclonal antigens and 53% lesions had CSiN scores &amp;lt;1. There was very little overlap in neoantigens across patients or between different lesions on the same patient, indicating a high degree of heterogeneity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The neoantigen landscape of MF is characterized by high neoantigen load and significant subclonality which could indicate potential challenges for immunotherapy in patients with advanced-stage disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2020.561234","type":"journal-article","created":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T02:36:54Z","timestamp":1606099014000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["The Neoantigen Landscape of Mycosis Fungoides"],"prefix":"10.3389","volume":"11","author":[{"given":"Arunima","family":"Sivanand","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dylan","family":"Hennessey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aishwarya","family":"Iyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"O\u2019Keefe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Surmanowicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gauravi","family":"Vaid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zixuan","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Gniadecki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,11,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002516","article-title":"Skin colonization by circulating neoplastic clones in cutaneous T-cell lymphoma","volume":"134","author":"Iyer","year":"2019","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-4099","article-title":"Clonotypic Diversity of the T-cell Receptor Corroborates the Immature Precursor Origin of Cutaneous T-cell Lymphoma","volume":"25","author":"Hamrouni","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.7665","article-title":"Survival outcomes and prognostic factors in mycosis fungoides\/S\u00e9zary syndrome: validation of the revised International Society for Cutaneous Lymphomas\/European Organisation for Research and Treatment of Cancer staging proposal","volume":"28","author":"Agar","year":"2010","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ejca.2017.02.027","article-title":"European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome - Update 2017","volume":"77","author":"Trautinger","year":"2017","journal-title":"Eur J Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1177\/1203475419867610","article-title":"Immunotherapy for Cutaneous T-Cell Lymphoma: Current Landscape and Future Developments","volume":"23","author":"Sivanand","year":"2019","journal-title":"J Cutan Med Surg"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.120571","article-title":"Psoriasiform mycosis fungoides with fatal outcome after treatment with cyclosporine","volume":"47","author":"Zackheim","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-1149","article-title":"Atopic dermatitis-like pre-S\u00e9zary syndrome: role of immunosuppression","volume":"91","author":"Soko\u0142owska-Wojdy\u0142o","year":"2011","journal-title":"Acta Derm Venereol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.19531","article-title":"Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy","volume":"8","author":"Medrano","year":"2017","journal-title":"Oncotarget"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00304","article-title":"Anti-tumor Activity of Toll-Like Receptor 7 Agonists","volume":"8","author":"Chi","year":"2017","journal-title":"Front Pharmacol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/sj.jidsp.5640188","article-title":"Photopheresis: clinical applications and mechanism of action","volume":"4","author":"Rook","year":"1999","journal-title":"J Invest Dermatol Symp Proc"},{"key":"B11","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/sj.bmt.1705968","article-title":"Haematopoietic stem cell transplantation for patients with primary cutaneous T-cell lymphoma","volume":"41","author":"Duarte","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.jdcr.2015.02.009","article-title":"Complete regression of mycosis fungoides after ipilimumab therapy for advanced melanoma","volume":"1","author":"Bar-Sela","year":"2015","journal-title":"JAAD Case Rep"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/mgg3.121","article-title":"Personalized treatment of S\u00e9zary syndrome by targeting a novel CTLA4:CD28 fusion","volume":"3","author":"Sekulic","year":"2015","journal-title":"Mol Genet Genomic Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.183.183","article-title":"A Phase 1 Study of Nivolumab in Combination with Ipilimumab for Relapsed or Refractory Hematologic Malignancies (CheckMate 039)","volume":"128","author":"Ansell","year":"2016","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01056","article-title":"Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and S\u00e9zary Syndrome: A Multicenter Phase II Study","volume":"38","author":"Khodadoust","year":"2020","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-08-2455","article-title":"Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate-pulsed dendritic cells","volume":"102","author":"Maier","year":"2003","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-11-4558","article-title":"Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cells","volume":"106","author":"Heinzerling","year":"2005","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-355222","article-title":"In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1\/2 study","volume":"119","author":"Kim","year":"2012","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1101\/804351","article-title":"Branched evolution and genomic intratumor heterogeneity in the pathogenesis of cutaneous T-cell lymphoma","author":"Iyer","year":"2019","journal-title":"bioRxiv"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"B24","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s13046-019-1085-3","article-title":"Challenges and potential of PD-1\/PD-L1 checkpoint blockade immunotherapy for glioblastoma","volume":"38","author":"Wang","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018027482","article-title":"Clonotypic heterogeneity in cutaneous T-cell lymphoma (mycosis fungoides) revealed by comprehensive whole-exome sequencing","volume":"3","author":"Iyer","year":"2019","journal-title":"Blood Adv"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-11-611194","article-title":"Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides","volume":"126","author":"McGirt","year":"2015","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3356","article-title":"Genomic landscape of cutaneous T cell lymphoma","volume":"47","author":"Choi","year":"2015","journal-title":"Nat Genet"},{"key":"B28","doi-asserted-by":"publisher","first-page":"11.10.1","DOI":"10.1002\/0471250953.bi1110s43","article-title":"From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline","volume":"43","author":"Van der Auwera","year":"2013","journal-title":"Curr Protoc Bioinf"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btu548","article-title":"OptiType: precision HLA typing from next-generation sequencing data","volume":"30","author":"Szolek","year":"2014","journal-title":"Bioinformatics"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3519","article-title":"Near-optimal probabilistic RNA-seq quantification","volume":"34","author":"Bray","year":"2016","journal-title":"Nat Biotechnol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-017-2001-3","article-title":"MuPeXI: prediction of neo-epitopes from tumor sequencing data","volume":"66","author":"Bjerregaard","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1700893","article-title":"NetMHCpan-4.0: Improved Peptide-MHC Class I Interaction Predictions Integrating Eluted Ligand and Peptide Binding Affinity Data","volume":"199","author":"Jurtz","year":"2017","journal-title":"J Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1038\/s41598-017-01617-3","article-title":"Benchmarking of RNA-sequencing analysis workflows using whole-transcriptome RT-qPCR expression data","volume":"7","author":"Everaert","year":"2017","journal-title":"Sci Rep"},{"key":"B34","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1186\/s12885-018-4325-6","article-title":"Population-level distribution and putative immunogenicity of cancer neoepitopes","volume":"18","author":"Wood","year":"2018","journal-title":"BMC Cancer"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gky1006","article-title":"The Immune Epitope Database (IEDB): 2018 update","volume":"47","author":"Vita","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gky1049","article-title":"UniProt: a worldwide hub of protein knowledge","volume":"47","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41592-018-0051-x","article-title":"Strelka2: fast and accurate calling of germline and somatic variants","volume":"15","author":"Kim","year":"2018","journal-title":"Nat Methods"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1101\/gr.180281.114","article-title":"TITAN: inference of copy number architectures in clonal cell populations from tumor whole-genome sequence data","volume":"24","author":"Ha","year":"2014","journal-title":"Genome Res"},{"key":"B39","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13059-015-0602-8","article-title":"PhyloWGS: reconstructing subclonal composition and evolution from whole-genome sequencing of tumors","volume":"16","author":"Deshwar","year":"2015","journal-title":"Genome Biol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"eaaz3199","DOI":"10.1126\/sciimmunol.aaz3199","article-title":"Tumor neoantigenicity assessment with CSiN score incorporates clonality and immunogenicity to predict immunotherapy outcomes","volume":"5","author":"Lu","year":"2020","journal-title":"Sci Immunol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1186\/1471-2105-15-293","article-title":"jvenn: an interactive Venn diagram viewer","volume":"15","author":"Bardou","year":"2014","journal-title":"BMC Bioinformatics"},{"key":"B42","doi-asserted-by":"publisher","first-page":"eaat1435","DOI":"10.1126\/sciimmunol.aat1435","article-title":"The immune system profoundly restricts intratumor genetic heterogeneity","volume":"3","author":"Milo","year":"2018","journal-title":"Sci Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3442","article-title":"The mutational landscape of cutaneous T cell lymphoma and S\u00e9zary syndrome","volume":"47","author":"da Silva Almeida","year":"2015","journal-title":"Nat Genet"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-02-768234","article-title":"Genomic analysis of 220 CTCLs identifies a novel recurrent gain-of-function alteration in RLTPR (p.Q575E)","volume":"130","author":"Park","year":"2017","journal-title":"Blood"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2018.04.005","article-title":"Update on Tumor Neoantigens and Their Utility: Why It Is Good to Be Different","volume":"39","author":"Lee","year":"2018","journal-title":"Trends Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30516-8","article-title":"Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis","volume":"18","author":"Turajlic","year":"2017","journal-title":"Lancet Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-011-0655-0","article-title":"Non-conventional sources of peptides presented by MHC class I","volume":"68","author":"Starck","year":"2011","journal-title":"Cell Mol Life Sci"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.21619","article-title":"Analysis of CTCL cell lines reveals important differences between mycosis fungoides\/S\u00e9zary syndrome leukemic cell lines","volume":"8","author":"Netchiporouk","year":"2017","journal-title":"Oncotarget"},{"key":"B49","doi-asserted-by":"publisher","first-page":"e1306618","DOI":"10.1080\/2162402X.2017.1306618","article-title":"Gene expression analysis in Cutaneous T-Cell Lymphomas (CTCL) highlights disease heterogeneity and potential diagnostic and prognostic indicators","volume":"6","author":"Litvinov","year":"2017","journal-title":"Oncoimmunology"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.154","article-title":"Targeting neoantigens to augment antitumour immunity","volume":"17","author":"Yarchoan","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.3390\/cancers11121824","article-title":"High Somatic Mutation and Neoantigen Burden Do Not Correlate with Decreased Progression-Free Survival in HCC Patients not Undergoing Immunotherapy","volume":"11","author":"Mauriello","year":"2019","journal-title":"Cancers"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.10.5696","article-title":"Positional scanning-synthetic peptide library-based analysis of self- and pathogen-derived peptide cross-reactivity with tumor-reactive Melan-A-specific CTL","volume":"169","author":"Rubio-Godoy","year":"2002","journal-title":"J Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.20094","article-title":"Human Mena protein, a serex-defined antigen overexpressed in breast cancer eliciting both humoral and CD8+ T-cell immune response","volume":"109","author":"Di Modugno","year":"2004","journal-title":"Int J Cancer"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1999.1585","article-title":"A human IAP-family gene, apollon, expressed in human brain cancer cells","volume":"264","author":"Chen","year":"1999","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.561234\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T02:36:57Z","timestamp":1606099017000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.561234\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,23]]},"references-count":54,"alternative-id":["10.3389\/fimmu.2020.561234"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.561234","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.01.22.915280","asserted-by":"object"}]},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,23]]},"article-number":"561234"}}